Suven Life Sciences
SUVENNSE

Suven Life Sciences

₹316.00-1.00 (0.32%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
311.20
Today’s high
320.05
52 week low
124.11
52 week high
371.00
Open price
315.00
Previous close
317.00
Live volume
5,88,295
Lower circuit
252.80
Upper circuit
379.20

Fundamentals

Market Cap
₹8,956Cr
ROE
-46.73%
P/E Ratio(TTM)
--
EPS(TTM)
-9.78
P/B Ratio
10.66
Dividend Yield
0.00%
Industry P/E
65.41
Book Value
29.74
Debt to Equity
0.03
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹8.30
+48.75%
Profit (Cr)
-₹45.60
+55.26%
-150-100-50050
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+209%
3Y CAGR+9%
Profit growthValue
1Y (TTM)-4%
3Y CAGR-9%

About

Suven Life Sciences is a biopharmaceutical company dedicated to discovering and developing novel pharmaceutical products for a wide range of Central Nervous System (CNS) disorders. The company's vision is to achieve a breakthrough innovation by singularly focusing on New Chemical Entities for CNS conditions, a commitment it has held for 20 years. It is uniquely positioned as the only Indian NCE-focused player with such a large basket of molecules specifically targeting disorders of the brain and spinal cord. Its core mission involves developing solutions for diseases with significant unmet medical needs, such as Alzheimer's, dementia, and narcolepsy, through its specialized research programs and clinical trials. Strategically, the company focuses on targets with novel and differentiated mechanisms of action, targeting indications that have high unmet needs and attractive commercial opportunities to ensure efficient development. This focused pursuit has resulted in a portfolio of 13 new chemical entities, which includes 7 assets in clinical stages and 6 projects in the research pipeline.;
CEO/MD
Shri Venkateswarlu Jasti
Founded in
1989
NSE symbol
SUVEN

Shareholding Pattern

Aug '26
Jun '26
Mar '26
Dec '25
Sep '25
Promoters
67.36%
Retail And Others
28.07%
Mutual Funds
2.08%
Other Domestic Institutions
1.31%
Foreign Institutions
1.18%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹317.35
+4.45 (1.42%)
L
    H
    3,524.4520.312.16
    Panacea BiotecPANACEABIO
    ₹441.20
    -4.20 (0.94%)
    L
      H
      2,736.68--3.28
      ₹117.90
      +3.90 (3.42%)
      L
        H
        515.85--12.87
        ₹3.04
        +0.07 (2.36%)
        L
          H
          22.50--2.69
          Livesquawk
          Suven Life Sciences reports successful Phase 1 results for SUVN-I6107. The company is advancing the SUVN-I6107 program to Phase 2 development.
          2026
          13
          May
          Quarterly & Annual Result
          Release date
          29
          Jan
          Quarterly Result
          Release date
          2025
          11
          Nov
          Quarterly Result
          Release date
          13
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks